Effects of G169R and P34S substitutions produced by mutations of CYP2D6*14 On the functional properties of CYP2D6 expressed in V79 cells

Drug Metabolism and Disposition

Volumn 30, Issue 11, 2002, Pages 1201-1205

  Shiraishi, Tomoko ^a,b   Hosokawa, Masakiyo ^a   Kobayashi, Kaoru ^a   Tainaka, Hitoshi ^a,c   Yamaura, Yoshiyuki ^a   Taguchi, Miwo ^a   Chiba, Kan ^a  

^a CHIBA UNIVERSITY   (Japan)

^b National Research Institute of Police Science   (Japan)

^c Asahi Techno Glass Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; COMPLEMENTARY DNA; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; O DEMETHYLASE; CYP2C6 PROTEIN, RAT; CYTOCHROME P450; ETHANOLAMINE DERIVATIVE; MESSENGER RNA; RECOMBINANT PROTEIN; STEROID 21 MONOOXYGENASE;

ALLELE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; DEMETHYLATION; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME MECHANISM; GENE EXPRESSION; GENE MUTATION; HYDROXYLATION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; CELL LINE; DEALKYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; METABOLISM; MUTATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA;

ALLELES; AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; CRICETINAE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DEXTROMETHORPHAN; DNA, COMPLEMENTARY; ETHANOLAMINES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROXYLATION; MUTATION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROID 21-HYDROXYLASE;

EID: 0036843606     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.11.1201     Document Type: Article

References (32)

1. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, and Bertilsson L (1995) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean. Japanese and Chinese subjects. Pharmacogenetics 5:159-164.
2. Daly AK, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, et al. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
3. Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, and Azuma J (2000) The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 380:303-308.
4. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, and Meyer UA (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond) 331:442-446.
5. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, and Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15-26.
6. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, and Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine [see comments]. Proc Natl Acad Sci USA 90:11825-11829.
7. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, and Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459.
8. Kagimoto M, Heim M, Kagimoto K, Zeugin T, and Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214.
9. Kronbach T, Mathys D, Gut J, Catin T, and Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24-32.
10. Kubota T, Yamaura Y, Ohkawa N, Hara H, and Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31-34.
11. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, and Huang JD (1995) Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 58:264-268.
12. Lewis DF (1998) The CYP2 family: Models, mutants and interactions. Xenobiotica 28:617-661.
13. Lewis DF, Eddershaw PJ, Goldfarb PS, and Tarbit MH (1997) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27:319-339.
14. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, and Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
15. Modi S, Paine MJ, Sutcliffe MJ, Lian LY, Primrose WU, Wolf CR, and Roberts GC (1996) A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 35:4540-4550.
16. Nishida Y, Fukuda T, Yamamoto I, and Azuma J (2000) CYP2D6 genotypes in a Japanese population: Low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10:567-570.
17. Oscarson M, Hidestrand M, Johansson I, and Ingelman-Sundberg M (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034-1040.
18. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, and Zanger UM (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10:577-581.
19. Ramamoorthy Y, Tyndale RF, and Sellers EM (2001) Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11:477-487.
20. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 29:413-580.
21. Sachse C, Brockmoller J, Bauer S, and Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences [see comments]. Am J Hum Genet 60:284-295.
22. Senda C, Yamaura Y, Kobayashi K, Fujii H, Minami H, Sasaki Y, Igarashi T, and Chiba K (2001) Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes. Br J Clin Pharmacol 52:100-103.
23. Shimada T, Tsumura F, Yamazaki H, Guengerich FP, and Inoue K (2001) Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 11:143-156.
24. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, and Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570-575.
25. Tseng CY, Wang SL, Lai MD, Lai ML, and Huang JD (1996) Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 60:177-182.
26. Tsuzuki D, Takemi C, Yamamoto S, Tamagake K, Imaoka S, Funae Y, Kataoka H, Shinoda S, and Narimatsu S (2001) Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae. Pharmacogenetics 11:709-718.
27. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, and Shader RI (1998) Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6 and CYP3A. J Pharm Pharmacol 50:997-1004.
28. Wang SL (1992) Phenotypes and Genotypes of Debrisoquine Hydroxylation Polymorphisms in Chinese. M.Sc. thesis, National Cheng Kung University, Tainan, Taiwan.
29. Wang SL, Huang JD, Lai MD, Liu BH, and Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418.
30. Wang SL, Lai MD, and Huang JD (1999) G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab Dispos 27:385-388.
31. Yamazaki S, Sato K, Suhara K, Sakaguchi M, Mihara K, and Omura T (1993) Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s. J Biochem (Tokyo) 114:652-657.
32. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, Kinoshita M, Sato K, Gonzalez FJ, and Kamataki T (1996) A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 6:395-401.